Keywords: alexion, acquires, prolifaron, mill, pharmaceuticals, acquired, privately-helddevelopment
Alexion acquires Prolifaron for $41 mill
Article | 25 September 2000
Alexion Pharmaceuticals has acquired Prolifaron, a privately-helddevelopment biopharmaceutical company based in San Diego, USA, in a stock deal valued at $41 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
